{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:17:00Z","timestamp":1786987020721,"version":"build-2736575974"},"reference-count":62,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clml.2025.06.019","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T12:08:14Z","timestamp":1750939694000},"page":"711-719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SOHO State of the Art Updates and Next Questions | Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Can Be Treated with Chemotherapy-Free Regimens without Transplant"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9702-8485","authenticated-orcid":false,"given":"Fadi G.","family":"Haddad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayastu","family":"Senapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.06.019_bib0001","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-023-01409-5","article-title":"The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades","volume":"16","author":"Jabbour","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.019_bib0002","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-020-00905-2","article-title":"Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions","volume":"13","author":"Samra","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2025.06.019_bib0003","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1182\/blood-2016-02-700153","article-title":"Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome\u2013positive ALL","volume":"128","author":"Rousselot","year":"2016","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2025.06.019_bib0004","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs Imatinib in frontline Philadelphia chromosome\u2013Positive acute lymphoblastic leukemia","volume":"331","author":"Jabbour","year":"2024","journal-title":"Jama"},{"issue":"7","key":"10.1016\/j.clml.2025.06.019_bib0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2025.06.019_bib0006","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ajh.25338","article-title":"Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American experts","volume":"94","author":"Short","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.06.019_bib0007","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1182\/blood-2018-99-111516","article-title":"Blinatumomab for minimal residual disease (MRD) in adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL): median overall survival (OS) is not reached in complete MRD responders at a median follow-up of 53.1 months","volume":"132","author":"Goekbuget","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.019_bib0008","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1038\/s41375-022-01668-0","article-title":"Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease","volume":"36","author":"Zuna","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.06.019_bib0009","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","article-title":"Impact of complete molecular response on survival in patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"128","author":"Short","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.019_bib0010","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2016-11-749978","article-title":"Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology","volume":"129","author":"Hovorkova","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.019_bib0011","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2017.176917","volume":"103","author":"Cazzaniga","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.06.019_bib0012","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41375-022-01736-5","article-title":"Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia","volume":"37","author":"Senapati","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.06.019_bib0013","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/leu.2008.386","article-title":"Quantification of fusion transcript reveals a subgroup with distinct biological properties and predicts relapse in BCR\/ABL-positive ALL: implications for residual disease monitoring","volume":"23","author":"Zaliova","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.06.019_bib0014","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1182\/bloodadvances.2022007378","article-title":"High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse","volume":"6","author":"Short","year":"2022","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.clml.2025.06.019_bib0015","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/ajh.26949","article-title":"Ultrasensitive NGS MRD assessment in Ph+\u2009ALL\u202f: prognostic impact and correlation with RT-PCR for BCR::ABL1","volume":"98","author":"Short","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.06.019_bib0016","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.24.00108","article-title":"Significance of measurable residual disease in adult Philadelphia chromosome\u2013positive ALL: a GRAAPH-2014 study","volume":"42","author":"Kim","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.06.019_bib0017","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1182\/blood-2024-203929","volume":"144","author":"Macaron","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.019_bib0018","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study","volume":"16","author":"Jabbour","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.06.019_bib0019","doi-asserted-by":"crossref","first-page":"e618","DOI":"10.1016\/S2352-3026(18)30176-5","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study","volume":"5","author":"Jabbour","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2025.06.019_bib0020","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.26816","article-title":"Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results","volume":"98","author":"Kantarjian","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.06.019_bib0021","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1002\/cncr.30231","article-title":"Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis","volume":"122","author":"Sasaki","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.06.019_bib0022","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.clml.2018.02.010","article-title":"Efficacy of Ponatinib versus earlier generation tyrosine kinase inhibitors for front-line treatment of newly diagnosed Philadelphia-positive acute lymphoblastic leukemia","volume":"18","author":"Jabbour","year":"2018","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2025.06.019_bib0023","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1002\/hem3.67","article-title":"Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: long-term results","volume":"8","author":"Ribera","year":"2024","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2025.06.019_bib0024","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/bloodadvances.2021004821","article-title":"INCB84344-201: ponatinib and steroids in frontline therapy for unfit patients with ph+ acute lymphoblastic leukemia","volume":"6","author":"Martinelli","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.06.019_bib0025","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1002\/cncr.33529","article-title":"Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.06.019_bib0026","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood.2022016194","article-title":"The role of allogeneic transplant for adult ph+ ALL in CR1 with complete molecular remission: a retrospective analysis","volume":"140","author":"Ghobadi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.019_bib0027","doi-asserted-by":"crossref","first-page":"7413","DOI":"10.1158\/1078-0432.CCR-11-1227","article-title":"CDKN2A\/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients","volume":"17","author":"Iacobucci","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2025.06.019_bib0028","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.3109\/10428194.2016.1144881","article-title":"Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665","volume":"57","author":"DeBoer","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2025.06.019_bib0029","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1080\/10428194.2017.1406933","article-title":"Combination of IKZF1 deletion and early molecular response show significant roles on prognostic stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia patients","volume":"59","author":"Li","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2025.06.019_bib0030","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.3324\/haematol.2020.260935","article-title":"A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients: final results of the GIMEMA LAL1509 protocol","volume":"106","author":"Chiaretti","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.06.019_bib0031","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the Dasatinib-Blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Foa","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.06.019_bib0032","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib\u2013Blinatumomab for ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2025.06.019_bib0033","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/s41375-021-01496-8","article-title":"Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib","volume":"36","author":"Sasaki","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.06.019_bib0034","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/ajh.24625","article-title":"Poor outcomes associated with +der(22)t(9;22) and \u22129\/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor","volume":"92","author":"Short","year":"2017","journal-title":"Am J Hematol"},{"issue":"36","key":"10.1016\/j.clml.2025.06.019_bib0035","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1200\/JCO.24.00272","article-title":"Results of the simultaneous combination of Ponatinib and Blinatumomab in Philadelphia chromosome-positive ALL","volume":"42","author":"Kantarjian","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.06.019_bib0036","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.clml.2017.08.101","article-title":"Safety and efficacy of Blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia","volume":"17","author":"Assi","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.06.019_bib0037","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/10428194.2020.1844198","article-title":"Blinatumomab\u2009+\u2009ponatinib for relapsed\/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults","volume":"62","author":"Couturier","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2025.06.019_bib0038","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.1182\/blood-2019-131838","article-title":"Blinatumomab in combination with tyrosine kinase inhibitors safely and effectively induces rapid, deep, and durable molecular responses in relapsed and refractory Philadelphia positive acute leukemias","volume":"134","author":"McCloskey","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.019_bib0039","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1182\/bloodadvances.2022008216","article-title":"Dasatinib\/prednisone induction followed by blinatumomab\/dasatinib in ph+ acute lymphoblastic leukemia","volume":"7","author":"Advani","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.06.019_bib0040","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2023-180204","article-title":"Long-term follow up for SWOG 1318: combination of Dasatinib, Prednisone, and Blinatumomab for older patients with Philadelphia-chromosome (Ph) positive acute lymphoblastic leukemia (ALL)","volume":"142","author":"Advani","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.019_bib0041","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2025.06.019_bib0042","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2024-206602","article-title":"Blinatumomab and Ponatinib for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: updated results and predictors of relapse","volume":"144","author":"Short","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.019_bib0043","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood-2024-207892","article-title":"Efficacy and toxicity of frontline Ponatinib plus Blinatumomab for adult ph+ ALL patients of all ages. Intermediate analysis of the Gimema ALL2820","volume":"144","author":"Chiaretti","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.019_bib0044","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/cncr.30130","article-title":"Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the","volume":"122","author":"Giebel","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.06.019_bib0045","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000510112","article-title":"Discontinuation of maintenance tyrosine kinase inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia outside of transplant","volume":"144","author":"Samra","year":"2021","journal-title":"Acta Haematologica"},{"issue":"5","key":"10.1016\/j.clml.2025.06.019_bib0046","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35773","article-title":"Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"131","author":"Kugler","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.06.019_bib0047","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1182\/blood-2023-187668","article-title":"Tyrosine kinase inhibitor (TKI) discontinuation in non-allografted ph+ acute lymphoblastic leukemia patients, a campus ALL real-life study","volume":"142","author":"Dragani","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.019_bib0048","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ajh.26550","article-title":"Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors","volume":"97","author":"Haddad","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.06.019_bib0049","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.06.019_bib0050","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1002\/cncr.29646","article-title":"Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"121","author":"Ravandi","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.06.019_bib0051","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1200\/JCO.2017.76.7228","article-title":"Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome\u2013Positive acute lymphoblastic leukemia: results of children\u2019s oncology Group trial AALL0622","volume":"36","author":"Slayton","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.06.019_bib0052","first-page":"E11","article-title":"Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia","volume":"98","author":"Paul","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.06.019_bib0053","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1002\/cncr.25008","article-title":"Central nervous system prophylaxis in adults with acute lymphoblastic leukemia","volume":"116","author":"Jabbour","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.06.019_bib0054","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1182\/blood.V72.5.1784.1784","article-title":"Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia","volume":"72","author":"Kantarjian","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.019_bib0055","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2005-11-4666","article-title":"Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII\/ECOG E2993","volume":"108","author":"Lazarus","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.019_bib0056","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2023-186225","article-title":"Dasatinib and CAR-T cell therapy for newly diagnosed ph-positive acute lymphoblastic leukemia in adults","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.019_bib0057","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood-2023-174246","article-title":"A phase I study of Asciminib (ABL001) in combination with Dasatinib and Prednisone for BCR-ABL1-positive ALL and blast phase CML in adults","volume":"142","author":"Luskin","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.019_bib0058","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1182\/blood-2023-187744","article-title":"Update of Olverembatinib (HQP1351) overcoming ponatinib and\/or asciminib resistance in patients (Pts) with heavily pretreated\/refractory chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL)","volume":"142","author":"Jabbour","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.019_bib0059","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2023-186139","article-title":"Frontline combination of 3 rd generation TKI Olverembatinib and Blinatumomab for ph+\/ph-like ALL patients","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.019_bib0060","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1182\/blood-2024-205232","article-title":"Olverembatinib-based therapy in patients with Philadelphia chromosome-positive acute leukemia: a multi-centre retrospective study from China","volume":"144","author":"Bao","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.06.019_bib0061","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/ajh.27227","article-title":"Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.clml.2025.06.019_bib0062","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/bloodadvances.2021004821","article-title":"INCB84344-201: ponatinib and steroids in frontline therapy of unfit patients with ph+ acute lymphoblastic leukemia","volume":"6","author":"Martinelli","year":"2021","journal-title":"Blood Adv"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:06:11Z","timestamp":1758603971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":62,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2152265025002356"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.019","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Can Be Treated with Chemotherapy-Free Regimens without Transplant","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}